Chinese CoronaVac Covid-19 vaccine has suffered a major setback after Brazil stopped clinical trials.
Brazilian regulator Anvisa said it had ruled to interrupt the clinical study of the CoronaVac vaccine after a serious adverse incident on October 29 involving a volunteer recipient.
Anvisa said it couldn’t give details on what happened because of privacy regulations, but that such incidents included; death, potentially fatal side effects, serious disability, hospitalization, birth defects etc.
Butantan Institute, the public health center coordinating the trials of the vaccine in Brazil, has however questioned Anvisa’s decision to cancel the vaccine trials.
- Trump’s Top Diplomat Mike Pompeo Promises Smooth Transition, But Not For Biden’s Administration
- Biden To Trump: Blocking Transition Is An Embarrassment And Will Not Help Your Legacy
- This Is What Magufuli told Joe Biden In His Massage Of Congratulation To The US President-elect
- Badi tells of Sonko over remark on heaps of rotten garbage in estates
- Mali’s Ex-President Amadou Toumani Toure Dies
- Nurses In Bondo Under Serious Condemnation For Investing In The Hearse Business
Butatan wants Anvisa to provide any clarification necessary on any adverse incident the clinical trials may have presented.
The Chinese vaccine has been caught up in a messy political battle in Brazil. Brazilian President Jair Bolsonaro has strongly opposed CoronaVac instead preparing a rival vaccine developed by Oxford University and pharmaceutical firm AstraZeneca.
Sao Paulo Governor Joao Doria however supports CoronaVac clinical trials, and was disappointed by Anvisa’s decision to suspend clinical trials of the Chinese vaccine.
The Sao Paulo state government said in a statement it was waiting along with the Butantan Institute for more information on the real reasons why why Anvisa suspended CoronaVac clinical trials.
CoronaVac vaccine was developed by Chinese pharmaceutical firm Sinovac Biotech. Apart from Brazil, Saudi Arabia also commenced CoronaVac vaccine clinical trials.